1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424
2. Cancer Tomorrow. https://gco.iarc.fr/tomorrow/graphic-isotype?type=1&type_sex=0&mode=population&sex=2&populations=900&cancers=25&age_group=value&apc_male=0&apc_female=0&single_unit=50000&print=0. Accessed 4 May 2020
3. Prat J (2012) New insights into ovarian cancer pathology. Ann Oncol. https://doi.org/10.1093/annonc/mds300
4. Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY (2016) Ovarian cancer. Nat Rev Dis Prim 2:1–22
5. Vergote I, Tropé CG, Amant F, et al (2010) Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer. N Engl J Med 363:943–953
6. Onda T, Satoh T, Saito T, et al (2016) Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602. Eur J Cancer 64:22–31
7. Liu EL, Mi RR, Wang DH, Wang LQ, Zhang YM, Chen W (2017) Application of combined intraperitoneal and intravenous neoadjuvant chemotherapy in senile patients with advanced ovarian cancer and massive ascites. Eur J Gynaecol Oncol 38:209–213
8. Pölcher M, Mahner S, Ortmann O, et al (2009) Neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian cancer - A prospective multicenter phase II trial (PRIMOVAR). Oncol Rep 22:605–613
9. van der Burg MEL, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, Lacave AJ, Nardi M, Renard J, Pecorelli S (1995) The Effect of Debulking Surgery after Induction Chemotherapy on the Prognosis in Advanced Epithelial Ovarian Cancer. N Engl J Med 332:629–634
10. Cooke SL, Brenton JD (2011) Evolution of platinum resistance in high-grade serous ovarian cancer. Lancet Oncol 12:1169–1174
11. Böhm S, Faruqi A, Said I, et al (2015) Chemotherapy response score: Development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma. J Clin Oncol 33:2457–2463
12. B7#x00F6;hm S, Le N, Lockley M, Brockbank E, Faruqi A, Said I, Jeyarajah A, Wuntakal R, Gilks B, Singh N (2019) Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: Updated Chemotherapy Response Score (CRS) results. Int J Gynecol Cancer 29:353–356
13. Glenn Mccluggage W, Judge MJ, Clarke BA, et al (2015) Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: Recommendations from the International Collaboration on Cancer Reporting (ICCR). Mod Pathol 28:1101–1122
14. Said I, Böhm S, Beasley J, et al (2017) The chemotherapy response score (CRS): Interobserver reproducibility in a simple and prognostically relevant system for reporting the histologic response to neoadjuvant chemotherapy in Tuboovarian High-grade Serous Carcinoma. Int J Gynecol Pathol 36:172–179
15. Ditzel HM, Strickland KC, Meserve EE, et al (2019) Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC). Int J Gynecol Pathol 38:230–240
16. Santoro A, Angelico G, Piermattei A, et al (2019) Pathological chemotherapy response score in patients affected by high grade serous ovarian carcinoma: The prognostic role of omental and ovarian residual disease. Front Oncol. https://doi.org/10.3389/fonc.2019.00778
17. Williams AT, Ganesan R (2020) Role of the pathologist in assessing response to treatment of ovarian and endometrial cancers. Histopathology 76:93–101
18. Coghlan E, Meniawy TM, Munro A, et al (2017) Prognostic role of histological tumor regression in patients receiving neoadjuvant chemotherapy for high-grade serous tubo-ovarian carcinoma. Int J Gynecol Cancer 27:708–713
19. Liontos M, Sotiropoulou M, Kaparelou M, et al (2020) Lymphocytic infiltration and Chemotherapy Response Score as prognostic markers in ovarian cancer patients treated with Neoadjuvant chemotherapy. Gynecol Oncol 157:599–605
20. Lee JY, Chung YS, Na K, Kim HM, Park CK, Nam EJ, Kim S, Kim SW, Kim YT, Kim HS (2017) External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma. J Gynecol Oncol. https://doi.org/10.3802/jgo.2017.28.e73
21. Rajkumar S, Polson A, Nath R, Lane G, Sayasneh A, Jakes A, Begum S, Mehra G (2018) Prognostic implications of histological tumor regression (Böhm’s score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma. Gynecol Oncol 151:264–268
22. Petrillo M, Zannoni GF, Tortorella L, Pedone Anchora L, Salutari V, Ercoli A, Margariti PA, Scambia G, Fagotti A (2014) Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. Am J Obstet Gynecol 211:632.e1-632.e8
23. Cohen PA, Powell A, Böhm S, et al (2019) Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data. Gynecol Oncol 154:441–448
24. Templeton AJ, McNamara MG, Šeruga B, et al (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: A systematic review and meta-analysis. J Natl Cancer Inst. https://doi.org/10.1093/jnci/dju124
25. Chen G, Zhu L, Yang Y, Long Y, Li X, Wang Y (2018) Prognostic role of neutrophil to lymphocyte ratio in ovarian cancer: A meta-analysis. Technol Cancer Res Treat. https://doi.org/10.1177/1533033818791500
26. Salman L, Sabah G, Jakobson-Setton A, Raban O, Yeoshoua E, Eitan R (2020) Neutrophil-to-lymphocyte ratio as a prognostic factor in advanced stage ovarian carcinoma treated with neoadjuvant chemotherapy. Int J Gynecol Obstet 148:102–106
27. Jeerakornpassawat D, Suprasert P (2020) Potential predictors for chemotherapeutic response and prognosis in epithelial ovarian, fallopian tube and primary peritoneal cancer patients treated with platinum-based chemotherapy. Obstet Gynecol Sci 63:55–63
28. Baert T, Van Camp J, Vanbrabant L, Busschaert P, Laenen A, Han S, Van Nieuwenhuysen E, Vergote I, Coosemans A (2018) Influence of CA125, platelet count and neutrophil to lymphocyte ratio on the immune system of ovarian cancer patients. Gynecol Oncol 150:31–37
29. Badora-Rybicka A, Nowara E, Starzyczny-Słota D (2016) Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio before chemotherapy as potential prognostic factors in patients with newly diagnosed epithelial ovarian cancer. ESMO Open. https://doi.org/10.1136/esmoopen-2016-000039
30. Yildiz Y, Kucukzeybek Y, Alacacioglu A, et al (2017) Prognostic value of preoperative neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with epithelial ovarian cancer. Eur J Gynaecol Oncol 38:444–448
31. Komura N, Mabuchi S, Yokoi E, Kozasa K, Kuroda H, Sasano T, Matsumoto Y, Kimura T (2018) Comparison of clinical utility between neutrophil count and neutrophil–lymphocyte ratio in patients with ovarian cancer: a single institutional experience and a literature review. Int J Clin Oncol 23:104–113
32. Zhou M, Li L, Wang X, Wang C, Wang D (2018) Neutrophil-to-Lymphocyte Ratio and Platelet Count Predict Long-Term Outcome of Stage IIIC Epithelial Ovarian Cancer. Cell Physiol Biochem 46:178–186
33. Wu Y yang, Qin Y yuan, Qin J qiu, Zhang X, Lin F quan (2019) Diagnostic value of derived neutrophil-to-lymphocyte ratio in patients with ovarian cancer. J Clin Lab Anal. https://doi.org/10.1002/jcla.22833
34. Chen L, Wang X, Shu J, Xu S, Wu Q, Yu Y (2019) Diagnostic value of serum D-dimer, CA125, and neutrophil-to-lymphocyte ratio in differentiating ovarian cancer and endometriosis. Int J Gynecol Obstet 147:212–218
35. YILDIRIM M, DEMIR CENDEK B, FILIZ AVSAR A (2015) Differentiation between benign and malignant ovarian masses in the preoperative period using neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios. Mol Clin Oncol 3:317–321
36. Aotsuka A, Matsumoto Y, Arimoto T, et al (2019) Interleukin-17 is associated with expression of programmed cell death 1 ligand 1 in ovarian carcinoma. Cancer Sci 110:3068–3078
37. Sanguinete MMM, Oliveira PH De, Martins-Filho A, Micheli DC, Tavares-Murta BM, Murta EFC, Nomelini RS (2017) Serum IL-6 and IL-8 Correlate with Prognostic Factors in Ovarian Cancer. Immunol Invest 46:677–688
38. Santos ID, Jammal MR, Silveira TP, Murta EFC, Nomelini RS (2019) Stromal IL2 is related to the neutrophil/lymphocyte ratio in epithelial ovarian cancer. Pathologica 111:62–66
39. Marchetti C, Romito A, Musella A, Santo G, Palaia I, Perniola G, Di Donato V, Muzii L, Benedetti Panici P (2018) Combined Plasma Fibrinogen and Neutrophil Lymphocyte Ratio in Ovarian Cancer Prognosis May Play a Role? Int J Gynecol Cancer 28:939–944
40. Ethier JL, Desautels DN, Templeton AJ, Oza A, Amir E, Lheureux S (2017) Is the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta-analysis. Gynecol Oncol 145:584–594
41. Yang J, Ma J, Cheng S, Wang Y (2020) The combination of plasma fibrinogen concentration and neutrophil lymphocyte ratio (F-NLR) as a prognostic factor of epithelial ovarian cancer. Onco Targets Ther 13:7283–7293
42. Farolfi A, Scarpi E, Greco F, et al (2020) Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study. Sci Rep 10:1–8
43. Kim YJ, Lee I, Chung YS, Nam EJ, Kim S, Kim SW, Kim YT, Lee JY (2018) Pretreatment neutrophil-to-lymphocyte ratio and its dynamic change during neoadjuvant chemotherapy as poor prognostic factors in advanced ovarian cancer. Obstet Gynecol Sci 61:227–234
44. Williams KA, Labidi-Galy SI, Terry KL, Vitonis AF, Welch WR, Goodman A, Cramer DW (2014) Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer. Gynecol Oncol 132:542–550
45. Grivennikov SI, Greten FR, Karin M (2010) Immunity, Inflammation, and Cancer. Cell 140:883–899
46. Bamias A, Gavalas NG, Karadimou A, Dimopoulos MA (2010) Immune response in ovarian cancer: How is the immune system involved in prognosis and therapy: Potential for treatment utilization. Clin Dev Immunol. https://doi.org/10.1155/2010/791603
47. Ocana A, Nieto-Jiménez C, Pandiella A, Templeton AJ (2017) Neutrophils in cancer: Prognostic role and therapeutic strategies. Mol Cancer. https://doi.org/10.1186/s12943-017-0707-7
48. Klink M, Jastrzembska K, Nowak M, Bednarska K, Szpakowski M, Szyllo K, Sulowska Z (2008) Ovarian cancer cells modulate human blood neutrophils response to activation in vitro. Scand J Immunol 68:328–336
49. Lee WJ, Ko SY, Mohamed MS, Kenny HA, Lengyel E, Naora H (2019) Neutrophils facilitate ovarian cancer premetastatic niche formation in the omentum. J Exp Med 216:176–194
50. Eo WK, Kim KH, Park EJ, Kim HY, Kim H bae, Koh SB, Namkung J (2018) Diagnostic accuracy of inflammatory markers for distinguishing malignant and benign ovarian masses. J Cancer 9:1165–1172
51. Yildirim MA, Seckin KD, Togrul C, Baser E, Karsli MF, Gungor T, Gulerman HC (2014) Roles of neutrophil/lymphocyte and platelet/lymphocyte ratios in the early diagnosis of malignant ovarian masses. Asian Pacific J Cancer Prev 15:6881–6885
52. Bakacak M, Serin S, Ercan Ö, Köstü B, Bostancı MS, Bakacak Z, Kıran H, Kıran G (2016) Utility of preoperative neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios to distinguish malignant from benign ovarian masses. J Turkish Ger Gynecol Assoc 17:21–25
53. Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim YT, Lee K (2009) Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother 58:15–23
54. Yang Z, Gu JH, Guo CS, Li XH, Yang WC (2017) Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival of epithelial ovarian cancer: A systematic review and meta-analysis of observational studies. Oncotarget 8:46414–46424
55. Asher V, Lee J, Innamaa A, Bali A (2011) Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer. Clin Transl Oncol 13:499–503
56. Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S, Thavaramara T (2012) Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. J Gynecol Oncol 23:265–273
57. Shrotriya S, Walsh D, Nowacki AS, Lorton C, Aktas A, Hullihen B, Benanni-Baiti N, Hauser K, Ayvaz S, Estfan B (2018) Serum c-reactive protein is an important and powerful prognostic biomarker in most adult solid tumors. PLoS One. https://doi.org/10.1371/journal.pone.0202555
58. Eo WK, Chang HJ, Kwon SH, et al (2016) The lymphocyte-monocyte ratio predicts patient survival and aggressiveness of ovarian cancer. J Cancer 7:289–296
59. Cai L, Song Y, Zhao X (2020) Prognostic significance of lymphocyte monocyte ratio in patients with ovarian cancer. Med (United States). https://doi.org/10.1097/MD.0000000000019638
60. Michaan N, Chong WY, Han NY, Lim MC, Park SY (2018) Prognostic Value of Pathologic Chemotherapy Response Score in Patients with Ovarian Cancer after Neoadjuvant Chemotherapy. Int J Gynecol Cancer 28:1676–1682
61. Lawson BC, Euscher ED, Bassett RL, Liu J, Ramalingam P, Zhong Y, Fleming ND, Malpica A (2020) A 3-Tier Chemotherapy Response Score for Ovarian/Fallopian Tube/Peritoneal High-grade Serous Carcinoma: Is it Clinically Relevant? Am J Surg Pathol 44:206–213
62. Lee YJ, Kim HS, Rim JH, Lee JY, Nam EJ, Kim SW, Kim S, Kim YT (2020) Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer. BMC Cancer. https://doi.org/10.1186/s12885-020-6688-8
63. Barrington DA, Felix AS, Owda R, et al (2020) Pathologic chemotherapy response score in epithelial ovarian cancer: Surgical, genetic, and survival considerations. Surg Oncol 34:40–45
64. Sassen S, Schmalfeldt B, Avril N, Kuhn W, Busch R, Höfler H, Fend F, Nährig J (2007) Histopathologic assessment of tumor regression after neoadjuvant chemotherapy in advanced-stage ovarian cancer. Hum Pathol 38:926–934
65. Liang M, Prendergast E, Staples J, Holschneider C, Cass I (2016) Complete Pathologic Response at Interval Debulking Surgery Following Neoadjuvant Chemotherapy Predicts Improved Survival in Women with Advanced Epithelial Ovarian Cancer in a Multi-institutional Cohort. Gynecol Oncol 143:197
66. Zhang L, Conejo-Garcia JR, Katsaros D, et al (2003) Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer. N Engl J Med 348:203–213